Vor Biopharma telitacicept post hoc Phase 3 analysis: 42% minimal symptom expression through 48 weeks
Vor Biopharma released a China Phase 3 post hoc analysis in generalized myasthenia gravis, reporting 42% minimal symptom expression and broad, sustained symptom relief through 48 weeks; safety was consistent with earlier reports.